Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-05-04
2010-06-22
Sajjadi, Fereydoun G (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S368000
Reexamination Certificate
active
07741310
ABSTRACT:
This invention relates to the novel identification of arginase as an enzymatic activity which can reverse inhibition of neuronal regeneration in the central and peripheral nervous system. Assays to monitor the effects of various agents on arginase expression and thus on neuronal regeneration and repair and to identify agents which will block or promote the inhibitory effects on neuronal outgrowth are provided. This invention also relates to compositions and methods using agents that can reverse the inhibitory effects of myelin on neural regeneration by affecting arginase activity or putrescine and derivative polyamine levels in a neuron. Methods for regulating and for promoting (or repressing) neuronal growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with conditions, disorders or diseases, comprising the step of administering at least one of the compositions according to this invention, are provided.
REFERENCES:
patent: 5395612 (1995-03-01), Griffith et al.
patent: 5932542 (1999-08-01), Filbin
patent: 6203792 (2001-03-01), Filbin
patent: 6387890 (2002-05-01), Christianson et al.
patent: 2003/0158262 (2003-08-01), Ramesh et al.
patent: 2003/0166562 (2003-09-01), Rothenberg et al.
patent: WO 93/00894 (1993-01-01), None
patent: WO 93/01300 (1993-01-01), None
patent: WO 97/01352 (1997-01-01), None
patent: WO 97/11965 (1997-04-01), None
patent: WO 97/30167 (1997-08-01), None
patent: WO 97/34567 (1997-09-01), None
patent: WO 97/39629 (1997-10-01), None
patent: WO 97/39754 (1997-10-01), None
patent: WO 99/14235 (1999-03-01), None
patent: WO 99/43345 (1999-09-01), None
patent: WO 00/18799 (2000-04-01), None
Esch et al. J. Neurosci. 18:4083-4095; 1998.
Mena et al. J. Neurochem. 65:2612-2620; 1995.
Lucchinetti et al. Curr. Opin. Neurol. 14:259-269; 2001.
Cai et al. Neuron. 22:89-101; 1999.
Angeles et al., “Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: Prevention of cell death by dibutyryl cyclic AMP,”Journal of Neurochemistry, 65:2612-2620 (1995). (Abstract only).
Bach et al., “Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway,”Proc. Nat'l. Acad. Sci. U.S.A., 96:5280-5285 (1999).
Baloh et al., “The GDNF family ligands and receptors—implications for neural development,”Curr. Opin. Neurobiol., 10:103-110 (2000).
Bernstein et al., “The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems,”Prog. Neurobiol., 57:485-505 (1999).
Braissant et al., “L-arginine uptake, the citrulline—NO cycle and arginase II in the rat brain: an in situ hybridization study,”Mol. Brain Res., 70:231-241 (1999).
Cai et al., “Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism,”Neuron, 22:89-101 (1999). (Abstract only).
Cavalli et al., “Mutagenesis of rat liver arginase expressed inEscherichia coli: role of conserved histidines,”Biochemistry, 33:10652-10657 (1994).
Chijiwa et al., “Inhibition of Forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC 12D Pheochromocytoma cells,”J. Biol. Chem., 265:5267-5272 (1990).
Chu et al., “Polyamines promote regeneration of injured axons of cultured rat hippocampal neurons,”Brain Res., 673:233-241 (1995).
Cox et al., “Arginase-Boronic Acid Complex Highlights a Physiological Role in Erectile Function,”Nature Struct. Biol., 6:1043-1047 (1999).
Croxford et al, “Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system,”Journal of Immunology, 160:5181-5187 (1998). (Abstract only).
Danzin et al., “Effect of alpha-difluoromethylomithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase, on polyamine levels in rat tissues,”Life Sci., 24:519-524 (1979).
Das et al., “Dexamethasone and dibutyryl cyclic amp induce the expression of alpha-1 antichymotrypsin in rat astrocytes implications for Alzheimer's disease,”Society for Neuroscience Abstracts, 17:1072 (1991). (Abstract only).
DeBellard et al., “Myelin-associated glycoprotein inhibits axonal regeneration from a variety of neurons via interaction with a sialoglycoprotein,”Mol. Cell Neurosci., 7:89-101 (1996).
Dornay et al., “Early polyamine treatment accelerates regeneration of rat sympathetic neurons,”Exp. Neurol., 92:665-674 (1986).
Esch et al., “Purification of a multipotent antideath activity from bovine liver and its identification as arginase: nitric oxide-independent inhibition of neuronal apoptosis,”J. Neurosci., 18:4083-4095 (1998).
Ghadge et al., “Mutant superoxide dismutase-1-linked familial amyotropic lateral sclerosis: molecular mechanisms of neuronal death and protection,”J. Neurosci., 17:8756-8766 (1997).
Gilad, et al., “Accelerated recovery following polyamines and aminoguanidine treatment after facial nerve injury in rats,”Brain Res., 724:141-144 (1996).
Gotoh and Mori, “Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells,”J. Cell Biol., 144:427-434 (1999).
Iniesta et al., “The inhibition of arginase by Nω-hydroxy-I-arginine controls the growth of Leishmania inside macrophages,”J. Exp. Med. 193:777-783 (2001).
Jelsma and Aguayo, “Trophic factors,”Curr. Opin. Neurobiol., 4:717-725 (1994).
Jenkinson et al., “Comparative properties of arginases,”Comp. Biochem. Physiol., 114B:107-132 (1996).
Jordan et al., “p53 expression induces apoptosis in hippocampal pyramidal neuron cultures,”J. Neurosci.,17:1397-1405 (1997).
Kase et al., “K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases,”Biochem. Biophys. Res. Commun., 142:436-440 (1987).
Kauppila et al., “Polyamines enhance recovery after sciatic nerve trauma in the rat,”Brain Res., 575:299-303 (1992).
Kauppila et al., “Putative stimulants for functional recovery after neural trauma: only spermine was effective,”Exp. Neurol., 99:50-58 (1988).
Khangulov et al., “L-Arginine binding to liver arginase requires proton transfer to gateway residue His141 and coordination of the guanidinium group to the dimangenese(II,II) center,”Biochemistry, 37:8539-8550 (1998).
Lindsay, “Neuron saving schemes,”Nature, 373:289-290 (1995).
Lindvall and Odin, “Clinical application of cell transplantation and neurotrophic factors in CNS disorders,”Current Opinion in Neurobiology, 4:752-757 (1994).
Ma, L. et al., “Cyclic AMP induces functional presynaptic boutons in hippocampal CA3-CA1 neuronal cultures,”Nature Neurosci., 2:24-30 (1999).
MacDonnell et al., “Nerve growth factor increases activity of ornithine decarboxylase in superior cervical ganglia of young rats,”Proc. Nat'l. Acad. Sci. U.S.A., 74:4681-4684 (1977).
Martino et al., “A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines,”Multiple Sclerosis, 4:222-227 (1998). (Abstract only).
Mason, “The GDNF Receptor: Recent Progress and Unanswered Questions,”Mol. Cell Neurosci., 8:112-119 (1996).
Meininger et al., “Proliferation of endothelial cells (EC) from diabetic BB rats is impaired,”J. Vasc. Research, 33 (S1):66 (262) (1996).
Mohaj
Filbin Marie T.
Ratan Rajiv R.
Beth Israel Deaconess Medical Center
Fish & Richardson P.C.
Research Foundation of the City University of New York
Sajjadi Fereydoun G
LandOfFree
Methods for stimulating nervous system regeneration and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for stimulating nervous system regeneration and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for stimulating nervous system regeneration and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4249281